Researchers at the University of Southern California will investigate whether mindfulness meditation can improve the effects of psilocybin-assisted therapy for...

A new analysis of brain activity under LSD suggests the psychedelic state involves a more complicated reorganisation of neural rhythms...

The US pharmaceutical giant has put $906 million behind a next-generation psychedelic for depression, giving one of the industry’s largest...

As psychedelic medicine moves towards pharmaceutical development, Incannex is attempting to take synthetic psilocybin through the clinical, regulatory and commercial...

New Mexico is continuing work on the regulatory framework for a medical psilocybin programme, with proposed rules covering the people,...

With six months to go until the inaugural PRS27 Psychedelic Roundtable Symposium, Psychedelics.media has announced that early bird tickets are...

Entropy Neurodynamics, GH Research and Helus Pharma are taking different approaches to a shared challenge: developing psychedelic medicines that can...

Emyria has begun treating its first patients at a new Sydney clinic, extending its Empax mental health services into New...

Melbourne-based Entropy Neurodynamics is advancing an intravenous psilocin programme spanning binge eating disorder, depression and other neuropsychiatric conditions, with recent...

Optimi Health has completed production of a new batch of 5mg naturally derived psilocybin capsules, with the same batch set...